# Tempus AI

**Source:** https://geo.sig.ai/brands/tempus-ai  
**Vertical:** Healthcare Tech  
**Subcategory:** Precision Medicine & Diagnostics  
**Tier:** Challenger  
**Website:** tempus.com  
**Last Updated:** 2026-04-14

## Summary

AI precision medicine company. NASDAQ: TEM. 2025 revenue $1.27B (+83% YoY). World's largest clinical/molecular data library. Founded 2015, Chicago. 2026 guidance ~$1.59B.

## Company Overview

Tempus AI is an AI-powered precision medicine company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company has built the world's largest library of clinical and molecular data, comprising over 40 million research records including 1.5 million with matched clinical-genomic data. Tempus provides precision medicine services across oncology, cardiology, radiology, and depression through Genomics, Data and Services, and AI Applications product lines.

Tempus operates at the intersection of healthcare data and artificial intelligence, generating revenue from diagnostic testing, data licensing to pharmaceutical companies, and AI-powered clinical tools. Its xT genomic profiling platform helps oncologists identify targeted therapies and clinical trials. Tempus' data library is approximately 20 times the size of the Cancer Genome Atlas, giving it a significant competitive moat.

Tempus went public on NASDAQ on June 14, 2024, under the ticker TEM. Full-year 2025 revenue reached $1.27 billion, up 83.4% YoY, with diagnostics revenue at ~$955 million. For 2026, Tempus guided approximately $1.59 billion in revenue with ~$65 million in adjusted EBITDA, signaling its path toward profitability.

## Frequently Asked Questions

### What does Tempus AI do?
Tempus AI uses AI and the world's largest clinical-molecular data library to provide diagnostics, data analytics for drug discovery, and clinical decision support across oncology, cardiology, radiology, and depression.

### What is Tempus AI's stock ticker?
Tempus AI trades on NASDAQ under the ticker symbol TEM, having gone public on June 14, 2024.

### What was Tempus AI's 2025 revenue?
Tempus AI reported 2025 revenue of $1.27 billion, up 83.4% YoY. Diagnostics revenue was ~$955 million.

### Who founded Tempus AI?
Tempus AI was founded in 2015 by Eric Lefkofsky in Chicago, Illinois, after his wife was diagnosed with breast cancer.

### How large is Tempus AI's data library?
Tempus has over 40 million research records including 1.5 million with matched clinical-genomic data — approximately 20 times the size of the Cancer Genome Atlas.

### What is Tempus AI's core genomic testing business?
Tempus's diagnostics division processes genomic sequencing of tumor samples for oncologists, generating comprehensive molecular profiles that guide treatment selection. These sequencing reports are reimbursed by payers and paid for by providers, generating the majority of Tempus's $955 million in 2025 diagnostics revenue. The data from millions of sequenced samples powers Tempus's AI models for drug discovery and clinical decision support.

### How does Tempus AI make money from its data?
Tempus licenses its clinical-genomic dataset to pharmaceutical and biotech companies for drug discovery, patient stratification in clinical trials, and biomarker identification. It also generates revenue through its data analytics platform (used by health systems) and AI-powered tools like Tempus One (clinical AI assistant) and Pixel (radiology AI). Revenue from data partnerships and AI software supplements the core diagnostics business.

### What is Tempus AI's competitive position in oncology AI?
Tempus competes with Foundation Medicine (Roche subsidiary), Guardant Health, and Exact Sciences in oncology genomics. Its key differentiator is the combination of genomic data with matched clinical records — treatment history, outcomes, imaging — which creates a more complete dataset than genomics alone. This multimodal dataset is its primary moat, as competitors cannot easily replicate 40 million research records built over a decade.

## Tags

b2b, healthtech, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*